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ORIGINAL ARTICLE
Predictors of Clinical Outcome in Children
Undergoing Orthotopic Liver Transplantation for
Acute and Chronic Liver Disease
Chris Rhee,1 Kiran Narsinh,1 Robert S. Venick,1 Ricardo A. Molina,1 Visal Nga,1 Rita Engelhardt,2 and
Martı´n G. Martı´n1
1Department of Pediatrics, Division of Gastroenterology, Mattel Children’s Hospital at UCLA and
2Department of Biostatistics at the David Geffen School of Medicine at UCLA, Los Angeles, CA
The current United Network for Organ Sharing (UNOS) policy is to allocate liver grafts to pediatric patients with chronic liver
disease based on the pediatric end-stage liver disease (PELD) scoring system, while children with fulminant hepatic failure may
be urgently listed as Status 1a. The objective of this study was to identify pre-transplant variables that inﬂuence patient and
graft survival in those children undergoing LTx (liver transplantion) for FHF (fulminant hepatic failure) compared to those
patients transplanted for extrahepatic biliary atresia (EHBA), a chronic form of liver disease. The UNOS Liver Transplant
Registry was examined for pediatric liver transplants performed for FHF and EHBA from 1987 to 2002. Variables that
inﬂuenced patient and graft survival were assessed using univariate and multivariate analysis. Kaplan-Meier analysis of FHF
and EHBA groups revealed that 5 year patient and graft survival were both signiﬁcantly worse (P  0.0001) in those patients
who underwent transplantation for FHF. Multivariate analysis of 29 variables subsequently revealed distinct sets of factors that
inﬂuenced patient and graft survival for both FHF and EHBA. These results conﬁrm that separate prioritizing systems for LTx
are needed for children with chronic liver disease and FHF; additionally, our ﬁndings illustrate that there are unique sets of
variables which predict survival following LTx for these two groups. Liver Transpl 12:1347-1356, 2006.
© 2006 AASLD.
Received August 24, 2005; accepted March 16, 2006.
Fulminant hepatic failure (FHF) is a poorly understood
disorder deﬁned as severe liver injury in the absence of
preexisting liver disease with the onset of encephalop-
athy in less than 8 weeks after symptoms have begun.1
In children, it is a rare but often times fatal disorder
that is secondary to a variety of causes including infec-
tion, toxin or drug-induced injury, and a variety of met-
abolic diseases. In contrast to the adult population, the
cause of FHF in children in the United States often is of
unknown etiology.2 Together, these may account for as
many as 50% of cases. In the absence of liver trans-
plantation (LTx), FHF of indeterminate etiology is asso-
ciated with a poor clinical prognosis with a fatality rate
as high as 90%.3 The treatment of FHF is primarily
supportive, and may require LTx if there are no signs of
recovery. Only a small fraction of patients with FHF
spontaneously regain normal function, meaning that
the majority of patients who do survive undergo LTx.
Unfortunately, pediatric LTx is limited by both the scar-
city of available donors and by the development of irre-
versible complications associated with liver failure that
make LTx contraindicated. Since most cases of FHF
require LTx within a period of days to weeks after the
onset of liver disease, clinicians must decide in a timely
manner when to list a child for transplantation before
his or her clinical condition deteriorates.
In contrast to the acute nature of FHF, extrahepatic
biliary atresia (EHBA) often leads to chronic end-stage
liver disease, and is the most common cause of pediat-
ric LTx. Children with EHBA generally present in early
infancy with cholestasis and, if diagnosed in a timely
manner, often undergo Kasai portoenterostomy during
the ﬁrst several months of life. Despite early surgical
intervention, more than half of the infants with EHBA
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for Organ Sharing; PELD, pediatric end-stage liver disease.
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progress over a period of months to years to end-stage
liver disease ultimately requiring LTx.4-6
In the past, regardless of etiology, the diagnosis of
end-stage liver disease in children, whether acute or
chronic, carried a poor prognosis. With the advent of
LTx, as well as advances in surgical techniques, immu-
nosuppresion and post-transplant medical care, the 5
year survival rate has improved to greater than 80%.3
The current United Network for Organ Sharing (UNOS)
policy is to allocate liver grafts to pediatric patients with
chronic liver disease based on the pediatric end-stage
liver disease (PELD) scoring system.7 This system was
implemented in 2002, and it uses important patient clin-
ical characteristics such as bilirubin, international nor-
malized ratio, albumin, growth failure, and age at trans-
plant in order to allocate donor livers. The premise behind
the PELD system is to predict a child’s risk of dying while
awaiting LTx, and to allocate organs to patients with the
greatest need. While this scoring system clearly pioneers
the distribution of donor livers with the use of evidence-
based data, it is limited to children with chronic liver
disease, and does not include speciﬁcs for those with
FHF. There are no evidence-based methods currently in
place to facilitate the distribution of livers to children with
FHF. Instead, the decision of whether or not to transplant
these patients is currently based primarily on the clinical
progression of their disease. Once children with FHF are
listed for LTx, they will now fall under the new status 1a
category, which requires them to have the onset of hepatic
encephalopathy within 8 weeks of their ﬁrst symptoms,
be in a pediatric ICU, and have one or more of the follow-
ing: ventilator dependence, dialysis/continuous veno-
venous hemoﬁltration or continuous venovenous hemo-
ﬁltration with dialysis, or INR  2.0. Given the short
supply of available organs, developing a ranking system
which prioritizes children with acute failure that are not
only in greatest need of a transplant, but who are also
most likely to survive surgery needs to be established.
Therefore, the objective of this study was to identify pre-
transplant variables that inﬂuence patient and graft sur-
vival in those children undergoing LTx for FHF andEHBA.
We hypothesized that due to the distinct features of FHF
and EHBA, the list of cofactors which predict outcomes in
these two groups would be quite different.
METHODS
A retrospective review of the UNOS nationwide data-
base was performed. The initial database contained
53,833 transplantations that occurred between Octo-
ber 1987 and May 2002 in the United States. 7,894 of
these transplants were performed in recipients 18 years
of age or less; 3,013 carried the diagnosis of either FHF
or EHBA. Retransplants (283 patients) were excluded
from analysis, leaving 2,730 pediatric patients who un-
derwent primary LTx for FHF or EHBA. Of these 2,730
patients included, 932 were transplanted for FHF and
1,798 for EHBA (Figure 1). Within the 932 patients with
FHF, 666 patients (72%) were diagnosed with FHF of
unknown etiology, 110 (12%) had a known viral hepa-
titis, 56 (6%) had acetaminophen-induced hepatic fail-
ure, 35 (4%) had FHF secondary to a drug other than
acetaminophen, and the remaining 60 (6%) patients had
a metabolic or other diagnosis as the cause of their FHF.
As mentioned, subjects were identiﬁed in the UNOS da-
tabase with the diagnosis of EHBA by the code 4270.
While the entire UNOS dataset contained more than
380 variables, we selected 29 potential peri-transplant
covariates (Figure 2). Based on literature in this ﬁeld
and experience at a major pediatric transplant center,
these cofactors were believed to be relevant in possibly
affecting clinical outcome and reﬂecting the degree of
liver disease. The variables can be classiﬁed into three
categories: 1) recipient variables (including epidemio-
logic information, pre-transplant clinical condition, and
pre-transplant laboratory values), 2) donor variables,
and 3) operative variables.
In this analysis, recipient status codes (alive, dead,
retransplanted and lost to follow-up) were assigned as
primary outcomes, and the follow-up days after the LTx
was used to determine the time-dependency of the clin-
ical outcome.
Statistical Analysis
The ﬁnal outcomes assessed were 5-year patient and
graft survival. All analyses were carried out separately
on FHF and EHBA patients using Kaplan-Meier meth-
ods. Univariate analysis was carried out on all 29 vari-
ables. Variables with a continuous scale were analyzed
by quartiles and variables with skewed distributions
were normalized using log transformation. Death and
graft failure rates as well as the hazard ratios were
calculated for each subcategory. Whenever possible,
Figure 1. The exclusion criteria for patients from the origi-
nal UNOS database of liver transplants.
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subcategories were grouped together when their death
or failure rates were similar and when the grouping was
clinically logical. This was done in order to simplify the
number of subcategories and increase statistical power
for multivariate analysis. Univariate tests of signiﬁ-
cance were carried out using the log rank tests. AllP-
values reported are two-sided. Those variables found to
be signiﬁcant (P  0.05) or approaching signiﬁcance
(deﬁned as P  0.20) at the univariate level were then
included as candidates for a multivariate model along
with any variables deemed clinically important,
whether they were statistically signiﬁcant or not.
The multivariate analyses were performed using
Cox proportional hazard models for time to patient
and graft loss. When two statistically signiﬁcant predic-
tors strongly correlatedwith each other (proxies) andwere
both clinically relevant, the one with the fewer missing
values was selected as a candidate for the ﬁnal model.
Due to different patterns of missing data, the number of
patients for analysis varied. Furthermore, different
model groups were evaluated by including or excluding
those variables with missing values. Speciﬁcally, we
compared the state versus region in the analysis of the
FHF group and compared the EHBA analysis with and
without bilirubin data. Missing data for other variables
included in the models were negligible and were ex-
cluded.
RESULTS
Kaplan-Meier Analysis
Curves for patient and graft survival for the FHF and
EHBA groups are shown in Figure 3. Five year patient
survival after transplantation was 89% in the EHBA
group vs. 73% in the FHF group (P  0.0001); ﬁve year
graft survival was 78% (EHBA) and 59% (FHF) respec-
tively (P  0.001).
Univariate Analysis
FHF group
Ten of the initial 29 variables examined, in univariate
analysis proved to be statistically signiﬁcant (P  0.05)
in inﬂuencing FHF patient survival post-transplant. All
of these variables were related to the recipient; they are
listed in Table 1A and marked with1.
Six additional variables that approached signiﬁcance
(P  0.20) were retained for the multivariate model
including: the state of residence, the UNOS region
where the patient was transplanted, initial waiting list
status code, serum creatinine at transplant, donor age,
and the distance from the donor hospital to the trans-
plant center.
All of the variables that were signiﬁcant in graft
survival are listed in Table 1A and labeled with 2. The
same variables which affected patient survival post-
transplant also proved to be signiﬁcant for graft
survival with the exception of three variables (the
recipient age, ventilator dependence at time of regis-
tration, and presence of encephalopathy at time of
transplant) which all only approached signiﬁcance.
Furthermore, four additional variables including the
patient’s serum creatinine and alkaline phosphatase
at transplant, the age of the donor, and the distance
of the donor from the transplant center were found to
be signiﬁcant in inﬂuencing graft survival in the FHF
group.
For graft survival, an additional 10 variables that
approached signiﬁcance (P  0.20) were retained as
candidates for the corresponding multivariate model.
These variables included recipient age, ventilator de-
pendence at time of registration, presence of encepha-
Figure 2. List of UNOS variables
Figure 3. Kaplan-Meier analysis of patient and graft survival over a 5-year period. Compared to the EHBA patients, long term
patient and graft survival is signiﬁcantly worse in those who underwent transplantation for FHF.
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lopathy at time of transplant, ethnicity, state of resi-
dence, initial waiting list status code, status code at
time of transplant, time on waiting list, serum albumin
at transplant, and organ donor type.
EHBA group
Within the EHBA group, we could fairly evaluate only
18 of the 29 variables since the remaining 11 variables
had too few patients or too many missing values. For
TABLE 1A. Univariate Analysis Demonstrating Signiﬁcant Variables in the FHF Group
Fulminant Hepatic Failure
Variable
Variable
category
Patient Survival Graft Survival
Death rate*
Death
rate
ratio p-value
Graft
failure
Graft
failure
rate ratio p-value
Age of recipient (years) 1 Age   2 10.313 1.000 0.008 1.401 1.000 0.0832
2  Age   7 6.716 0.651 1.036 0.740
7  Age   14 4.431 0.430 0.840 0.599
Age  14 7.123 0.691 1.250 0.892
Grade 3, 4 Yes 10.206 1.000 0.017 1.436 1.000 0.0775
encephalopathy at
transplant 1
No 6.096 0.597 1.084 0.755
Ventilator at Yes 14.052 1.000 0.037 1.905 1.000 0.1640
registration 1 No 6.065 0.432 1.010 0.530
Ventilator at transplant Yes 10.967 1.000 .0001 1.558 1.000 .0001
1, 2 No 4.508 0.411 0.868 0.557
Life support at Yes 14.052 1.000 0.037 1.905 1.000 .0001
registration 1, 2 No 6.065 0.432 1.010 0.530
Life support at Yes 10.927 1.000 .0001 1.563 1.000 .0001
transplant 1, 2 No 3.575 0.327 0.721 0.461
Medical condition at
registration 1, 2
Requiring ICU
care
8.655 1.000 0.003 1.310 1.000 0.0246
Hospitalized, but
not in ICU
6.716 0.776 1.023 0.781
Not hospitalized 3.446 0.398 0.875 0.668
Medical condition at
transplant 1, 2
Requiring ICU
care
8.208 1.000 .0001 1.225 1.000 0.0033
Not requiring
ICU care
2.943 0.359 0.743 0.606
Blood type mismatch 1, 2 Yes 12.42 1.000 0.0001 1.866 1.000 .0001
No 6.477 0.512 1.046 0.560
More than one Yes 2.423 1.000 0.0003 12.601 1.000 .0001
transplant 1, 2 No 7.193 2.968 0.830 0.066
Donor age (years) 2 Donor age   7 5.651 1.000 0.137 0.884 1.000 0.01
7  Donor age 
 34
6.545 1.158 1.040 1.176
Donor age  34 11.189 1.980 1.797 2.033
Serum creatinine at
transplant 2
log creat  
0.523
8.698 1.000 0.107 1.256 1.000 0.015
()0.523  log
creat  0.09
5.672 0.652 0.937 0.746
log creat 
0.097
9.400 1.081 1.482 1.180
Distance of donor distance   29 6.979 1.000 0.120 1.115 1.000 0.039
hospital to transplant
center (miles) 2
29  distance 
 588
6.752 0.967 1.082 0.953
distance  588 7.771 1.113 1.243 1.116
Serum alkaline log alk   2.361 6.576 1.000 0.265 1.058 1.000 0.028
phosphatase at
transplant 2
log alk  2.361 16.082 2.446 2.297 2.172
*Death rate and graft failure rate (listed per 1,000 person months of follow-up)
1  Signiﬁcant variable in patient survival (P  0.05)
2  Signiﬁcant variable in graft survival (P  0.05)
1350 RHEE ET AL.
LIVER TRANSPLANTATION.DOI 10.1002/lt. Published on behalf of the American Association for the Study of Liver Diseases
instance, due to the chronic nature of EHBA very few
patients in this group had evidence of either encepha-
lopathy or received blood type mismatch transplants.
The following variables were excluded from analysis:
patient gender, ABO mismatch, more than one trans-
plant, initial waiting list status, waiting list status at
time of transplant, grades three-four encephalopathy at
registration or LTx, life support at registration or LTx, or
ventilator requirement at time of transplant. Of the 18
variables that were candidates for univariate analysis
TABLE 1B. Univariate Analysis Demonstrating Signiﬁcant Variables in the EHBA Group
Extrahepatic Biliary Atresia
Variable
Variable
category
Patient Survival Graft Survival
Death rate*
Death
rate
ratio p-value
Graft
failure
Graft failure
rate ratio p-value
Medical condition at
registration 2
Requiring
ICU care
2.117 1.000 0.2859 0.645 1.000 .0001
Not requiring
ICU care
2.028 0.958 0.420 0.651
Medical condition at
transplant 1, 2
Requiring
ICU care
3.118 1.000 0.0005 0.638 1.000 .0001
Not requiring
ICU care
1.801 0.578 0.403 0.632
Ventilator at Yes 10.749 1.000 0.0002 3.822 1.000 .0001
registration 1, 2 No 1.922 0.179 0.410 0.107
Donor age (years) 1, 2 Age   6 1.427 1.000 0.0078 0.373 1.000 0.0030
Age  6 2.856 2.001 0.543 1.456
Liver organ type 1, 2 Whole graft 1.405 1.000 .0001 0.321 1.000 .0001
Split graft 3.729 2.653 0.790 2.461
Serum creatinine at
transplant 1
log creat  
0.699
0.937 1.000 0.0057 0.296 1.000 0.2297
log creat 
0.699
2.205 2.353 0.469 1.587
Ethnicity 1 White 1.823 1.000 0.0209 0.404 1.000 0.606
Black 2.551 1.400 0.500 1.237
Hispanic 1.367 0.750 0.478 1.184
Asian 3.017 1.655 0.503 1.244
UNOS region where
transplanted 1, 2
1, 6, 11 5.185 1.000 0.0036 0.767 1.000 0.0029
2 0.916 0.177 0.260 0.339
3, 4 2.943 0.568 0.632 0.823
5 1.996 0.385 0.408 0.531
7, 8 1.766 0.341 0.442 0.576
9, 10 2.314 0.446 0.481 0.627
Serum albumin at
transplant 2
log alb  
0.431
2.579 1.000 0.2960 0.555 1.000 0.049
0.431  log
alb  
0.544
2.063 0.800 0.452 0.815
log alb 
0.544
1.451 0.563 0.334 0.601
Serum AST at
transplant 2
log AST  
2.064
1.735 1.000 0.3294 0.381 1.000 0.006
log AST 
2.064
5.446 3.138 1.214 3.183
Serum ALT at
transplant 2
log ALT  
1.875
1.689 1.000 0.1741 0.372 1.000 0.003
log ALT 
1.875
5.952 3.524 1.313 3.527
Days on waiting list 2 Wait   88 1.893 1.000 0.0606 0.467 1.000 0.009
Wait  88 2.150 1.135 0.409 0.876
*Death rate and graft failure rate (listed per 1,000 person months of follow-up)
1  Signiﬁcant variable in patient survival (P  0.05)
2  Signiﬁcant variable in graft survival (P  0.05)
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in the EHBA group, seven variables proved to be signif-
icant in patient survival and ten were signiﬁcant in graft
survival. These are listed and labeled appropriately in
Table 1B.
Multivariate Analysis:
FHF group
Multivariate analysis of the FHF group revealed seven
ﬁnal variables that were simultaneously statistically
signiﬁcant for inﬂuencing patient survival (Table 2).
These variables were the recipient’s age, donor’s age,
the UNOS region of transplant, blood type mismatch,
the presence of life support at registration and at time of
transplant, and whether the patient underwent more
than one LTx. With regards to graft survival in the FHF
group, the UNOS region no longer was signiﬁcant, while
ventilator requirement at registration gained signiﬁ-
cance.
Extrahepatic biliary atresia analysis
In the multivariate analysis of the EHBA group for pa-
tient survival, the ﬁnal list of predictors that were sta-
tistically signiﬁcant included medical condition at time
of transplant, region of transplant, and the type of graft
received (Table 2). In addition to the same variables that
inﬂuenced patient survival, ventilator requirement at
registration also proved to be a signiﬁcant factor in
affecting graft survival in those patients transplanted
for EHBA.
DISCUSSION
FHF in children is a poorly understood disease process,
as evidenced by the lack of studies in the pediatric
transplant literature.8,9 Our Kaplan-Meier analysis of
5-year patient and graft survival reveals that both out-
comes are signiﬁcantly worse in those children who
underwent transplantation for FHF as compared to
EHBA. This ﬁnding has been suggested in previous
studies with 1-year patient and graft survival rates.10
Furthermore, multivariate analysis of the Studies of
Pediatric Liver Transplantation database has shown
that the diagnosis of FHF is a risk factor for both death
and graft loss after LTx.11 The strength of our analysis
rests in the large sample size included in this study.
TABLE 2. Cox Proportional Hazard Multivariate Analysis Demonstrating Signiﬁcant Variables (P  .05 are in Bold)
in the FHF and EHBA Groups
Fulminant Hepatic Failure
Variable Variable category
Patient Survival Graft Survival
Death Rate
Ratio p-value
Graft Failure
Rate Ratio p-value
Patient age (years) Age   2 2.552 .0001 1.902 0.0002
2  Age   7 1.691 0.019 1.391 0.0532
7  Age   14 1.000 1.000
Age  14 1.305 0.234 1.336 0.0803
Region Region 1, 9, 10 1.404 0.191 1.081 0.6905
Region 2, 3, 11 1.404 0.151 1.216 0.2534
Region 4 1.931 0.019 1.272 0.2965
Region 6, 7 1.678 0.046 1.445 0.0553
Region 8 1.923 0.017 1.403 0.1157
Region 5 1.000 1.000
Blood type mismatch 1.611 0.011 1.545 0.0041
Life support at transplant 2.270 .0001 1.692 .0001
Life support at registration 1.489 0.015 1.579 0.0014
Donor age (years) Donor age   7 1.000 — 1.000 —
7  Donor age   34 1.437 0.051 1.274 0.1032
Donor age  34 1.820 0.007 1.750 0.0014
Ventilator at registration — — 0.705 0.0290
Extrahepatic Biliary Atresia
Medical condition at transpla Not requiring ICU care 0.499 0.0001 0.698 0.0068
Requiring ICU care 1.000 — 1.000 —
UNOS region Region 1, 6, 11 4.317 .0001 2.264 0.0002
Region 3, 4 2.269 0.0045 1.731 0.0024
Region 5 1.518 0.1788 1.066 0.7496
Region 7, 8 1.662 0.0623 1.465 0.0209
Region 9, 10 1.910 0.0372 1.497 0.0447
Region 2 1.000 — 1.000 —
Type of liver graft Split graft 1.761 0.0004 1.692 .0001
Whole graft 1.000 — 1.000 —
Ventilator at registration — — 4.481 .0001
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Due to the distinct nature of FHF and EHBA, we
hypothesized that each group would have a unique set
of variables that predict clinical outcomes. By perform-
ing univariate and multivariate analysis of the UNOS
database from 1987 to 2002 we identiﬁed several dis-
tinct variables that inﬂuence the prognosis of pediatric
LTx in FHF as compared to EHBA. The signiﬁcance of
this is that it demonstrates clear differences between
these two groups of patients, indicating that the expe-
rience compiled from chronic liver disease patients can-
not be simply extrapolated to the FHF group. Our data
also conﬁrms that the current method of allocation of
liver grafts to pediatric transplant candidates by the
PELD scoring system does not and should not pertain
to children with FHF. The PELD scoring system was
developed using the Studies of Pediatric Liver Trans-
plantation database of pre-transplant children with
chronic liver disease and evaluated the endpoints of
death and transfer to the intensive care unit.7 The
PELD system attempts to predict the probability of mor-
tality while on the waiting list as a means of allocating
donor grafts in a fair and equitable manner. Fortu-
nately, modiﬁcations made to the Organ Procurement
TransplantationNetwork/UNOS policies in August of
2005 seek to address this issue. For pediatric patients
Status 1 has been modiﬁed into statuses 1A and 1B.
Status 1A will include revised deﬁnitions for FHF in
that all patients in this category must have onset of
hepatic encephalopathy within 8 weeks of the ﬁrst
symptoms of liver disease, absence of pre-existing liver
disease, location in an ICU, plus one of the following: a)
ventilator dependence, b) dialysis or CVVH or CVVHD,
or c) internal normalized ratio 2.0. The intent of these
modiﬁcations is to ensure that the allocation priority
assigned to Status 1A will be reserved for those children
with FHF with the most immediate need for a liver
transplant.
Our current study evaluates how various pre- and
post-operative variables inﬂuence the risk of patient
and graft survival following LTx for children with both
chronic and acute liver disease. The signiﬁcance of
these individual risk factors in post-LTx patient and
graft survival is addressed below.
Age of Recipient
While some studies on pediatric LTx have shown no
difference in patient or graft survival by age,12,13 others
have demonstrated that recipient age signiﬁcantly in-
ﬂuences clinical outcome.3,14,15 Once the distinction
was made between FHF and EHBA patients, our anal-
ysis demonstrates that recipients less than seven years
of age who underwent LTx for FHF had worse patient
and graft survival rates when compared to older chil-
dren (Table 2). This trend has been appreciated in a
single-center pediatric study which described that re-
cipient age of less than four years independently corre-
lated with patient survival in children transplanted for
FHF.8 While small sample size was a limiting factor in
the aforementioned study, the use of the UNOS data-
base lends more credibility to this observation. Possible
explanations of this trend may involve the age-speciﬁc
differences in the underlying causes of FHF as well as
the more difﬁcult perioperative issues associated with
younger patients. Further analysis of this important
trend is required. Interestingly, the same trend was not
appreciated in the group transplanted for EHBA. Pos-
sible reasons for this may include the fact that there is
certainly more subjectivity as to when to refer and list
children with FHF (as opposed to EHBA) for LTx. It is
possible that younger children with FHF may not toler-
ate the delay in waiting for organs and LTx as well as
children with chronic liver disease. The overall pre-LTx
health status of children with FHF may be more tenu-
ous than those with EHBA due to the fact that FHF may
cause dysfunction of multiple organ systems resulting
in increased ICP, cardiovascular instability, acute renal
failure, coagulopathy and increased risk of infection .16
In patients with EHBA, age at transplantation, when
stratiﬁed by1 or1 year old, has recently been shown
in the SPLIT database to be a signiﬁcant factor in pre-
dicting post-LT mortality. 17 This illustrates that the
variability in many studies with regards to the impor-
tance of age may have a lot to do with the age cutoffs
used for stratiﬁcation and analysis.
Age of the Donor
While younger donor age previously has been reported
to correlate with improved clinical outcomes in pediat-
ric patients undergoing LTx, the majority of these stud-
ies focus on patients with chronic liver disease.12,18
Our univariate analysis concurred with these results in
patients with EHBA, in whom the death rate risk ratio
was 2.0 for donors older than 6 years of age (Table 1B).
However, our evaluation of the EHBA group by multi-
variate analysis did not reveal the donor age to signiﬁ-
cantly inﬂuence patient or graft survival.
In our evaluation of pediatric patients speciﬁcally
transplanted for FHF, the donor age proved to be a
signiﬁcant variable that inﬂuenced patient and graft
survival. Donor age greater than 34 correlated with a
worse outcome for both patient and graft survival, do-
nor age from 7 to 34 years of age approached signiﬁ-
cance for patient survival, while donors less than 7
years old had the best outcome in the FHF group (Table
2). Fortunately, the new UNOS criteria helps to ensure
that pediatric donors will go to pediatric recipients.
Type of Graft
One of the many challenges in pediatric LTX includes
the common use of reduced organ grafts. The current
shortage of organ donors has led to the use of seg-
mental grafts in order to provide timely liver trans-
plants to children. Reports of increased graft loss
with segmental grafts 13,19-21 have been conﬁrmed by
some transplant programs, while others report more
encouraging results.22,23 Most of these studies do not
distinguish between the indications for LTx. In our
multivariate analysis of patients transplanted for
FHF, the type of graft received did not signiﬁcantly
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alter either patient or graft survival. However, receiv-
ing a reduced graft for the indication of EHBA nega-
tively inﬂuenced both graft (P  0.0001) and patient
survival (P  0.05) (Table 2). The ﬁnding of segmental
grafts as a risk factor for patient survival in EHBA
also supports a study by Goss et al. which evaluated
190 patients undergoing LTx for EHBA,24 and a later
multi-center analysis performed by the same
group.25 A possible explanation for this trend is that
children with EHBA may tend to receive reduced-size
grafts in emergent settings when their pre-LTx health
is compromised. Additionally, children with EHBA on
average undergo LTx at an earlier age than patients
with FHF, which may predispose them to the techni-
cal challenges associated with small graft size, and
prolonged stay in the intensive care unit. This trend
warrants further study which may beneﬁt from strat-
iﬁcation of FHF by etiology and age.
ABO Mismatch
In a recent multivariate analysis of 500 pediatric
LTxs, most of whom had chronic liver disease, ABO
mismatch independently correlated with worse pa-
tient and graft survival.12 Due to the infrequent need
to transplant ABO mismatched organs in patients
with chronic liver conditions such as EHBA, ABO
mismatch was not analyzed in the EHBA group. How-
ever, mismatch was found to be a negative factor in
the FHF group, impacting both patient (P  0.006)
and graft survival (P  0.004). ABO mismatch has
been reported in additional studies as predictive of
worse graft survival in LTx for FHF.26
Children who receive ABO transplants are often quite
sick at the time of LTx, and the physicians taking care
of them are forced, so to speak, into accepting ABO
mismatched organs for fear that the child may die on
the waiting list while awaiting a properly matched or-
gan. In this sense ABO mismatch may be somewhat of
a confounding variable in that it interacts with vari-
ables such as life support, medical condition and ven-
tilator status. Following this logic, in our multivariate
analysis of the FHF group, ABO mismatch was still
signiﬁcant although to a lesser extent than it was in
univariate analysis.
Medical Condition/Life Support/Ventilator
Dependency
In multivariate analysis of patients transplanted for
FHF, life support at registration and at transplant sig-
niﬁcantly inﬂuenced patient and graft survival (Table
2). In the EHBA group, the medical condition of the
patient at time of transplant was a factor that signiﬁ-
cantly inﬂuenced patient and graft survival. Ventilator
dependency at registration was found to negatively in-
ﬂuence only graft survival in both EHBA and FHF
groups. This is in contrast to the ﬁndings described in
two studies where ventilator dependency pre-trans-
plant correlated with actual survival of pediatric pa-
tients transplanted for FHF.8,9
UNOS Region
Regional differences inﬂuencing patient and/or graft
survival in both groups were noted in our analysis.
There is likely variability in referral patterns to trans-
plant centers, as well as in the timing of registration
and transplantation that may contribute to the dispar-
ity recorded in this study. The importance of referral
patterns in inﬂuencing clinical outcome was previously
reported in patients with FHF where it was noted that
delays in transferring patients to a transplant center
signiﬁcantly affected the likelihood of survival.27 Other
studies have observed that donor selection criteria
changed within transplant centers with additional ex-
perience.28
In terms of average waiting list time for pediatric
patients, it has been shown that regional variations
clearly exist.29 The same analysis has revealed statisti-
cally signiﬁcant differences by UNOS regions in the
mean PELD scores and the percentage of children in the
ICU at the time of transplant, perhaps suggesting re-
gional variation in acuity of illness. Other studies have
also demonstrated signiﬁcant variation across the Or-
gan Procurement Transplanation Network regions be-
tween PELD scores at the time of listing (range: 2-10)
and transplant (range: 7-24).30 Along these same lines
it has been demonstrated that there is considerable
variability in the relative availability of pediatric livers
by region, and in the rate of pediatric liver transplanta-
tion relative to the census for a given region.31 In terms
of regional mortality rates on the pediatric waiting list
there is little data available in the literature, and again
while it is certainly an important area of study, it is one
which is outside of the scope of this study. This regional
variability warrants further study.
Repeat Transplants
Although we excluded actual repeat transplant epi-
sodes from our study, those patients who requiredmore
than one transplant were evaluated separately. By def-
inition, repeat transplants indicated graft failure. While
this variable could not be analyzed in the EHBA group,
those patients who underwent LTx for FHF and re-
quired more than one transplant proved in univariate
analysis to have a worse prognosis for patient survival
(Table 1A). This is likely reﬂective of multi-system organ
impairment prior to re-LTx.
Negative Findings
Serum creatinine and albumin at time of transplant, as
well as prothrombin time and bilirubin levels from reg-
istration and transplant were not found to be signiﬁ-
cant in affecting patient or graft survival in those pa-
tients with FHF or EHBA in our study 32. In terms of
prothrombin time not being a signiﬁcant predictor, this
is likely in part due to the fact that that prolonged INR
is often actively corrected in pediatric patients awaiting
LTx in order to avoid complications associated with
bleeding. This may make prothrombin time a less reli-
able indicator of a child’s true synthetic liver function.
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Another variable which was not a signiﬁcant predic-
tor in multivariate analysis of patient or graft survival
for either group (EHBA or FHF), was time on the waiting
list. This is likely because other variables more accu-
rately describe and predict the gravity of a patient’s
health status at time of transplant. These include vari-
ables such as whether or not a patient requires ICU
care or life support at the time of transplant, serum
creatinine at time of transplant, and whether a patient
received an ABO incompatible liver. The concept that
patients’ health status at the time of transplant plays
an important role in survival is certainly not disputed
by our analysis. We have simply shown that there are
variables whichmore accurately describe patient acuity
at the time of transplant and probability of surviving
liver transplantation than the length of time on the
waiting list. It is important to note that our analysis
only examined survival for patients who make it to
transplant. It does not measure the risk of dying on the
waitlist as a result of longer wait times.
Study Strengths and Limitations
In comparison to prior small single center studies, the
use of the UNOS database has granted us a large sam-
ple size in order to understand important cofactors in
pediatric liver transplant outcome. More speciﬁcally
our study includes the largest number of pediatric sub-
jects who have undergone LTx for FHF. At the same
time, a certain limitation of the UNOS transplant data-
set is that the information contained within it was ac-
quired from transplant centers with the objective of
assuring proper allocation of organs. The use of multi-
ple centers and covariates means that there is no as-
surance of data accuracy or completeness. An addi-
tional limitation is that the UNOS database does not
include those patients who were not listed either be-
cause of precipitous recovery or clinical deterioration,
including those patients never transferred to a trans-
plant program. Furthermore, the UNOS database does
not collect certain covariates, such as evidence of bone
marrow dysfunction pre-LTx, which may be important
predictors of outcome in children with FHF. Aplastic
anemia is a relatively common and potentially signiﬁ-
cant problem in a subset of patients with fulminant
hepatic failure. While our group and others have pub-
lished single center experiences with aplastic anemia
and FHF,33,34 it would have been helpful to study such
a problem using the extensive UNOS database. Unfor-
tunately, aplastic anemia is not a variable which is
captured in the UNOS database, therefore, it is not
included this analysis.
Another weakness of the database is that the clinical
laboratory values are limited to single points in time at
registration and transplant, rather than a continuous
trend; hence, peak laboratory values could not be eval-
uated as in other studies.35,36 Nonetheless, the dataset
contains valuable information that can be used to as-
sess the transplant process.
Conclusion
In summary, there are several pre-transplant variables
that inﬂuence pediatric patient and graft survival in
FHF and EHBA. Given the current short supply of avail-
able organs, it is not only crucial that clinicians should
be able to identify those patients in greatest need of a
transplant, but also those who are most likely to survive
surgery. This study provides such a list of important
variables for children with both acute and chronic
forms of liver disease requiring transplantation.
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